Children and adolescents living with multiple sclerosis (MS) seem to benefit at least as much — and for some outcomes, significantly more — from Ocrevus (ocrelizumab) as from treatment with […]
The post ECTRIMS 2025: Ocrevus as good as Gilenya for treating MS in children appeared first on Multiple Sclerosis News Today.
Source: multiplesclerosisnewstoday.com